Generic Zeposia Availability
Last updated on Apr 10, 2025.
Zeposia is a brand name of ozanimod, approved by the FDA in the following formulation(s):
ZEPOSIA (ozanimod hydrochloride - capsule;oral)
-
Manufacturer: BRISTOL
Approval date: March 25, 2020
Strength(s): EQ 0.23MG BASE [RLD], EQ 0.46MG BASE [RLD], EQ 0.92MG BASE [RLD]
Is there a generic version of Zeposia available?
No. There is currently no therapeutically equivalent version of Zeposia available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zeposia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
Patent 10,239,846
Issued: March 26, 2019
Inventor(s): Martinborough Esther & Boehm Marcus F. & Yeager Adam Richard & Tamiya Junko & Huang Liming & Brahmachary Enugurthi & Moorjani Manisha & Timony Gregg Alan & Brooks Jennifer L. & Peach Robert & Scott Fiona Lorraine & Hanson Michael Allen
Assignee(s): CELGENE INTERNATIONAL II SÀRLCompounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.
Patent expiration dates:
- November 15, 2030✓
- November 15, 2030
-
Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
Patent 11,680,050
Issued: June 20, 2023
Inventor(s): Chen; Minhua et al.
Assignee(s): RECEPTOS LLC (New York, NY)The present disclosure is directed to novel crystalline forms of ozanimod and ozanimod hydrochloride, as well as preparation method thereof. Said crystalline forms of ozanimod and ozanimod hydrochloride can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, melting point, stability, dissolution, bioavailability and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development. ##STR00001##
Patent expiration dates:
- September 30, 2038✓✓✓
- September 30, 2038✓✓✓
- September 30, 2038
-
Modulators of sphingosine phosphate receptors
Patent 8,481,573
Issued: July 9, 2013
Inventor(s): Roberts Edward & Rosen Hugh & Brown Steven & Guerrero Miguel A. & Peng Xuemei & Poddutoori Ramulu
Assignee(s): The Scripps Research InstituteCompounds of the following generic structure are provided:
Patent expiration dates:
- March 24, 2033✓✓✓
- March 24, 2033
-
Modulators of sphingosine phosphate receptors
Patent 8,796,318
Issued: August 5, 2014
Inventor(s): Roberts Edward & Rosen Hugh & Brown Steven & Guerrero Miguel A. & Peng Xuemei & Poddutoori Ramulu
Assignee(s): The Scripps Research InstituteCompounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.
Patent expiration dates:
- May 14, 2029✓✓
- May 14, 2029
-
Modulators of sphingosine phosphate receptors
Patent 9,382,217
Issued: July 5, 2016
Inventor(s): Roberts Edward & Rosen Hugh & Brown Steven & Guerrero Miguel A. & Peng Xuemei & Poddutoori Ramulu
Assignee(s): The Scripps Research InstituteCompounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.
Patent expiration dates:
- May 14, 2029✓
- May 14, 2029
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- March 25, 2025 - NEW CHEMICAL ENTITY
- August 30, 2027 - INFORMATION ADDED TO THE LABELING TO INCLUDE RESULTS FROM A STUDY TO FULFILL POSTMARKETINGREQUIREMENT 3809-5
More about Zeposia (ozanimod)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (8)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: selective immunosuppressants
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
